bremelanotide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-05-24 and is reviewed periodically as new material appears.
Compared with the related compound melanotan II, PT-141 shows markedly weaker activation of receptors tied to pigmentation. This difference stems from subtle structural variations that alter affinity distribution across receptor subtypes. Investigators propose that such selectivity produces a different side effect profile in specific applications. However, downstream consequences of prolonged receptor activation remain uncertain in the literature. Published studies do not fully agree on the duration of signaling pathway activity and the mechanisms of desensitization.
From a pharmacokinetic standpoint, the peptide is usually delivered by injection because oral bioavailability is very low; proteases in the digestive tract degrade it rapidly. After subcutaneous administration, plasma concentrations reach a peak within roughly one hour. Its elimination half-life is relatively short, with most reports placing it in the range of a few hours. Nasal formulations have also been examined, though absorption varies widely between individuals. Metabolism proceeds mainly through peptidase cleavage, and the resulting products are excreted by the kidneys.
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
| Property | Value | Notes |
|---|---|---|
| Primary target | Melanocortin receptors | Mainly the MC4R subtype |
| Route of administration | Injection | Typically subcutaneous |
| Time to peak | About 60 minutes | After subcutaneous dosing |
| Elimination half-life | Roughly 2 to 3 hours | Values vary across reports |
| Metabolic pathway | Peptidase hydrolysis | Cleared by the kidneys |
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
== External links == Anatomy photo: Digestive/mammal/system1/system10 - Comparative Organology at University of California, Davis - "Mammal, whole system (LM, Low)" Histology image: 55_07 at the University of Oklahoma Health Sciences Center (vermiform appendix)
A polycyclic aromatic hydrocarbon (PAH) is any member of a class of organic compounds that is composed of multiple fused aromatic rings. Most are produced by the incomplete combustion of organic matter—by engine exhaust fumes, tobacco, incinerators, in roasted meats and cereals, or when biomass burns at lower temperatures as in forest fires. The simplest representative is naphthalene, having two aromatic rings, and the three-ring compounds anthracene and phenanthrene. PAHs are uncharged, non-polar and planar. Many are colorless. Many of them are also found in fossil fuel deposits such as coal and in petroleum. Exposure to PAHs can lead to different types of cancer, fetal development complications, and cardiovascular issues. Polycyclic aromatic hydrocarbons are discussed as possible starting materials for abiotic syntheses of materials required by the earliest forms of life.
==== March ==== On 1 March, clashes broke out between Syrian caretaker government forces and local Druze armed groups responsible for community protection in Jaramana, during the security operation launched by Syrian authorities on the suburb. Members of the Jaramana Shield Brigade were involved in the clashes. During a violent altercation which erupted in Al-Seuof Square between two General Security Service members and local armed residents, one local gunman sustained serious injuries, requiring hospitalization, while authorities took the two security personnel into custody. In the clash at Al-Seuof Square, the wounded local gunman was taken to Al-Mujtahed Hospital for medical treatment. But Hay'at Tahrir al-Sham militants arrived at the hospital where the situation escalated when one of the wounded man's escorts allegedly made blasphemous remarks about Allah. This prompted members of Hayat Tahrir al-Sham present at the hospital to physically assault and subsequently detain the companions, resulting in one confirmed fatality among security forces. The clashes ended on 2 March 2025, after the entry of General Security Service into Jaramana. A meeting was held in March 2025 between Druze spiritual leader Hikmat al-Hijri, Yahya Al-Hajjar, the head of the Men of Dignity, Suleiman Abdul Baqi, the leader of Ahrar Jabal al-Arab, and Shakib Azam, the leader of Al-Jabal Brigade, in which it was agreed that the General Security Service would be "re-activated" in the governorate, as long as the people involved were from Suwayda.
Sources: en.wikipedia.org
Nurses affiliated with the New Zealand Nurses Organisation in Auckland and Whangārei commence industrial action to protest staff shortages. A member of the New Zealand Defence Force pleads guilty before a court-martial to attempted espionage on behalf of a foreign country, in the first espionage conviction in New Zealand. He is sentenced to two years' imprisonment on 20 August. 19 August: The Interislander and Bluebridge cancel several ferry sailings due to strong swells in the Cook Strait. Foreign Minister Winston Peters recalls Trevor Mallard as New Zealand ambassador to Ireland, designating Angela Hassan-Sharp as his successor. Employees of media company Stuff vote to take strike action to protest their employer's plan to split their collective bargaining agreement. 20 August: Secondary school teachers affiliated with the Post Primary Teachers' Association went on strike for a day after rejecting the Government's one percent pay rise offer. The New Zealand Cabinet agrees to draft legislation banning greyhound racing in New Zealand. 21 August: Defence Minister Judith Collins and Foreign Minister Winston Peters announce that the Government will purchase two new Airbus A321XLR jets and five MH-60R Seahawks for the New Zealand Defence Force. Carter Holt Harvey proposes closing its Eves Valley Sawmill in the Tasman District, potentially affecting 142 jobs. Airliner Jetstar admits to 20 charges of breaching the Fair Trading Act 1986 by misleading customers about compensation.
== A == Acetylcholine A neurotransmitter involved in muscle activation, attention, arousal, and memory. It acts at both nicotinic and muscarinic receptors throughout the central and peripheral nervous systems. Achromatopsia Loss of color vision as a result of damage to extrastriate visual cortex. Action Potential A rapid electrical signal that travels down the axon of a neuron. Activation The time-dependent opening of ion channels in response to a stimulus, typically membrane depolarization. Adaptation The phenomenon of sensory receptor adjustment to different levels of stimulation; critical for allowing sensory systems to operate over a wide dynamic range. Adenylyl cyclase Membrane-bound enzyme that can be activated by G-proteins to catalyze the synthesis of cyclic AMP from ATP. Adrenal cortex The outer region of the adrenal gland, responsible for producing steroid hormones such as cortisol and aldosterone, which regulate metabolism and stress responses. Adrenal medulla The central part of the adrenal gland that, under visceral motor stimulation, secretes epinephrine and norepinephrine into the bloodstream. Adrenaline See epinephrine. Afferent nerve fiber An axon that conducts action potentials from the periphery toward the central nervous system. Agnosia The inability to name objects, typically resulting from brain damage in the occipital or temporal lobes. Agonist A chemical that binds to and activates a receptor, mimicking the action of a natural neurotransmitter.
During the Allied occupation of Germany after World War II, internal borders were redrawn by the Allied military governments. New states were established in all four zones of occupation: Bremen, Hesse, Württemberg-Baden, and Bavaria in the American zone; Hamburg, Schleswig-Holstein, Lower Saxony, and North Rhine-Westphalia in the British zone; Rhineland-Palatinate, Baden, Württemberg-Hohenzollern and the Saarland – which later received a special status – in the French zone; Mecklenburg(-Vorpommern), Brandenburg, Saxony, Saxony-Anhalt, and Thuringia in the Soviet zone. No single state comprised more than 30% of either population or territory; this was intended to prevent any one state from being as dominant within Germany as Prussia had been in the past. Initially, only seven of the pre-War states remained: Baden (in part), Bavaria (reduced in size), Bremen, Hamburg, Hesse (enlarged), Saxony, and Thuringia. The states with hyphenated names, such as Rhineland-Palatinate, North Rhine-Westphalia, and Saxony-Anhalt, owed their existence to the occupation powers and were created out of mergers of former Prussian provinces and smaller states. Former German territory that lay east of the Oder-Neisse line fell under either Polish or Soviet administration but attempts were made at least symbolically not to abandon sovereignty well into the 1960s.
Sources: en.wikipedia.org
It primarily activates specific subtypes in the melanocortin receptor family. These receptors are G protein-coupled and mediate signaling mainly within the central nervous system.
It activates pigmentation-related receptors more weakly. This selectivity is thought to alter its side effect profile.
Injection is the most common route. Nasal administration has been studied as well, though absorption varies considerably.
PT-141 was the development code used for bremelanotide during its preclinical and early clinical programme. The peptide is now generally referred to by its international nonproprietary name.